Precision BioSciences Inc (DTIL) FinancialsDTILPrecision BioSciences Inc

Precision BioSciences Inc (DTIL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Therapeutics, accounting for 84.6% of total sales, equivalent to $5.36M. Another important revenue stream is Food. Understanding this composition is critical for investors evaluating how DTIL navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Precision BioSciences Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -260.53%, while the net margin is -471.42%. These profitability ratios, combined with a Return on Equity (ROE) of -135.15%, provide a clear picture of how effectively DTIL converts its operational activities into shareholder value.

In the context of the broader market, DTIL competes directly with industry leaders such as PEPG and VYGR. With a market capitalization of $205.08M, it holds a significant position in the sector. When comparing efficiency, DTIL's gross margin of 100.00% stands against PEPG's N/A and VYGR's 100.00%. Such benchmarking helps identify whether Precision BioSciences Inc is trading at a premium or discount relative to its financial performance.

The company reported a net loss of $32.7 million in Q2 2026, but revenue exceeded expectations at $10.84 million, indicating potential for future growth. The forward P/E ratio is 11.78, suggesting the stock may be undervalued based on future earnings.